111 related articles for article (PubMed ID: 2095203)
1. Preparation and characterization of conjugates of recombinant CD4 and deglycosylated ricin A chain using different cross-linkers.
Ghetie V; Till MA; Ghetie MA; Tucker T; Porter J; Patzer EJ; Richardson JA; Uhr JW; Vitetta ES
Bioconjug Chem; 1990; 1(1):24-31. PubMed ID: 2095203
[TBL] [Abstract][Full Text] [Related]
2. Large scale preparation of an immunoconjugate constructed with human recombinant CD4 and deglycosylated ricin A chain.
Ghetie V; Till MA; Ghetie MA; Uhr JW; Vitetta ES
J Immunol Methods; 1990 Jan; 126(1):135-41. PubMed ID: 2303721
[TBL] [Abstract][Full Text] [Related]
3. HIV-infected cells are killed by rCD4-ricin A chain.
Till MA; Ghetie V; Gregory T; Patzer EJ; Porter JP; Uhr JW; Capon DJ; Vitetta ES
Science; 1988 Nov; 242(4882):1166-8. PubMed ID: 2847316
[TBL] [Abstract][Full Text] [Related]
4. Immunoconjugates containing ricin A chain and either human anti-gp41 or CD4 kill H9 cells infected with different isolates of HIV, but do not inhibit normal T or B cell function.
Till MA; Ghetie V; May RD; Auerbach PC; Zolla-Pazner S; Gorny MK; Gregory T; Uhr JW; Vitetta ES
J Acquir Immune Defic Syndr (1988); 1990; 3(6):609-14. PubMed ID: 2140127
[TBL] [Abstract][Full Text] [Related]
5. CD4 peptide-protein conjugates, but not recombinant human CD4, bind to recombinant gp120 from the human immunodeficiency virus in the presence of serum from AIDS patients.
Ghetie V; Slaughter C; Wheeler HT; Uhr JW; Vitetta ES
Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5690-3. PubMed ID: 2062847
[TBL] [Abstract][Full Text] [Related]
6. Purification and properties of immunotoxins containing one vs. two deglycosylated ricin A chains.
Ghetie V; Swindell E; Uhr JW; Vitetta ES
J Immunol Methods; 1993 Nov; 166(1):117-22. PubMed ID: 8228282
[TBL] [Abstract][Full Text] [Related]
7. CD4-affinity purification of recombinant and native HIV gp120 and comparison of the affinity constants for the receptor.
Moritz D; Dirckx L; Mous J; Schneider J
FEBS Lett; 1990 Nov; 275(1-2):146-50. PubMed ID: 2261984
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a soluble form of human CD4. Peptide analyses confirm the expected amino acid sequence, identify glycosylation sites and demonstrate the presence of three disulfide bonds.
Harris RJ; Chamow SM; Gregory TJ; Spellman MW
Eur J Biochem; 1990 Mar; 188(2):291-300. PubMed ID: 2318210
[TBL] [Abstract][Full Text] [Related]
9. Covalent binding of human alpha 2-macroglobulin to deglycosylated ricin A chain and its immunotoxins.
Ghetie MA; Uhr JW; Vitetta ES
Cancer Res; 1991 Mar; 51(5):1482-7. PubMed ID: 1705175
[TBL] [Abstract][Full Text] [Related]
10. Red blood cells bearing CD4 bind to gp120 covered plates and aggregate with cells expressing gp120.
Arvinte T; Schulz B; Madoulet C; Nicolau C
J Acquir Immune Defic Syndr (1988); 1990; 3(11):1041-5. PubMed ID: 1698964
[TBL] [Abstract][Full Text] [Related]
11. Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4.
Byrn RA; Sekigawa I; Chamow SM; Johnson JS; Gregory TJ; Capon DJ; Groopman JE
J Virol; 1989 Oct; 63(10):4370-5. PubMed ID: 2550671
[TBL] [Abstract][Full Text] [Related]
12. The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond.
Ghetie V; Thorpe P; Ghetie MA; Knowles P; Uhr JW; Vitetta ES
J Immunol Methods; 1991 Sep; 142(2):223-30. PubMed ID: 1717600
[TBL] [Abstract][Full Text] [Related]
13. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Blakey DC; Newell DR
Cancer Res; 1988 Nov; 48(22):6396-403. PubMed ID: 3263186
[TBL] [Abstract][Full Text] [Related]
14. Renaturated ricin toxin B chain made in Escherichia coli is soluble, stable, and biologically active.
Tonevitsky A; Toptygin A; Agapov I; Pfueller U; Frankel A
Biochem Mol Biol Int; 1994 Apr; 32(6):1139-46. PubMed ID: 8061631
[TBL] [Abstract][Full Text] [Related]
15. Deamidation of soluble CD4 at asparagine-52 results in reduced binding capacity for the HIV-1 envelope glycoprotein gp120.
Teshima G; Porter J; Yim K; Ling V; Guzzetta A
Biochemistry; 1991 Apr; 30(16):3916-22. PubMed ID: 2018763
[TBL] [Abstract][Full Text] [Related]
16. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.
Kahn JO; Allan JD; Hodges TL; Kaplan LD; Arri CJ; Fitch HF; Izu AE; Mordenti J; Sherwin JE; Groopman JE
Ann Intern Med; 1990 Feb; 112(4):254-61. PubMed ID: 2297204
[TBL] [Abstract][Full Text] [Related]
17. Selective cytotoxicity of a novel immunotoxin based on pulchellin A chain for cells expressing HIV envelope.
Sadraeian M; Guimarães FEG; Araújo APU; Worthylake DK; LeCour LJ; Pincus SH
Sci Rep; 2017 Aug; 7(1):7579. PubMed ID: 28790381
[TBL] [Abstract][Full Text] [Related]
18. Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development.
Scandella CJ; Kilpatrick J; Lidster W; Parker C; Moore JP; Moore GK; Mann KA; Brown P; Coates S; Chapman B
AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1233-44. PubMed ID: 8142140
[TBL] [Abstract][Full Text] [Related]
19. Purification of ricin A1, A2, and B chains and characterization of their toxicity.
Fulton RJ; Blakey DC; Knowles PP; Uhr JW; Thorpe PE; Vitetta ES
J Biol Chem; 1986 Apr; 261(12):5314-9. PubMed ID: 3957927
[TBL] [Abstract][Full Text] [Related]
20. Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus.
Pincus SH; McClure J
Proc Natl Acad Sci U S A; 1993 Jan; 90(1):332-6. PubMed ID: 8419938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
